Abstract: Disclosed herein are methods and compositions to improve the solubility of therapeutic agents. In one embodiment, a method of improving solubility of a therapeutic agent includes mixing fullerene in a lipid solution to form a lipofullerene mixture, and mixing the therapeutic agent with the lipofullerene mixture.

Abstract: In some embodiments, a lipofullerene-saccharide compound and a method of inhibiting and/or ameliorating metastasis of neoplastic cells using said compound is disclosed herein. The lipofullerene-saccharide compound may be used in therapeutically effective doses to inhibit the metastasis of neoplasms in mammals. In some embodiments, the method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation including a lipofullerene-saccharide compound. In some embodiments, the lipofullerene-saccharide compound may be formed by reacting (e.g., coupling) a lipid and a saccharide with a fullerene. In some embodiments, neoplastic cells may include pancreatic cancer cells, prostate cancer cells, lung cancer cells, breast cancer cells, colon cancer cells, and/or brain cancer cells.

Abstract: In some embodiments, a lipofullerene-saccharide compound and a method of inhibiting and/or ameliorating metastasis of neoplastic cells using said compound is disclosed herein. The lipofullerene-saccharide compound may be used in therapeutically effective doses to inhibit the metastasis of neoplasms in mammals. In some embodiments, the method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation including a lipofullerene-saccharide compound. In some embodiments, the lipofullerene-saccharide compound may be formed by reacting (e.g., coupling) a lipid and a saccharide with a fullerene. In some embodiments, neoplastic cells may include pancreatic cancer cells, prostate cancer cells, lung cancer cells, breast cancer cells, colon cancer cells, and/or brain cancer cells.

Abstract: Disclosed herein are methods and compositions to improve the solubility of therapeutic agents. In one embodiment, a method of improving solubility of a therapeutic agent includes mixing fullerene in a lipid solution to form a lipofullerene mixture, and mixing the therapeutic agent with the lipofullerene mixture.

Abstract: Methods relating to methods for producing a needle coke precursor from slurry oil having low levels of nitrogen and sulfur. Nitrogen-containing compounds are removed by chromatography, followed by hydrotreating at relatively mild conditions that focus on the more easily-removed sulfur-containing compounds while largely preserving aromatic content of the slurry oil. The resulting needle coke precursor can be converted to a premium needle coke in a delayed coking system.

Abstract: In some embodiments, a chemical composition may include C60, serrapeptase, or a tetrapeptide. The tetrapeptide may include ALA,GLU,ASP,GLY. In some embodiments, the chemical composition may include a dipeptide. The dipeptide may include carnosine or camatine. In some embodiments, the chemical composition may include at least one lipid. One or more components of the chemical composition may be suspended in and/or dissolved in the at least one lipid. At least one lipid may include olive oil or mussel oil. In some embodiments, a method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation comprising the chemical composition. The method may include inhibiting and/or ameliorating inflammation and/or a malady associated with inflammation. In some embodiments, the subject may include a human or a nonhuman mammal. Nonhuman mammals may include equines, canines, or felines.

Abstract: In some embodiments, a chemical composition may include C60, serrapeptase, or a tetrapeptide. The tetrapeptide may include ALA,GLU,ASP,GLY. In some embodiments, the chemical composition may include a dipeptide. The dipeptide may include carnosine or camatine. In some embodiments, the chemical composition may include at least one lipid. One or more components of the chemical composition may be suspended in and/or dissolved in the at least one lipid. At least one lipid may include olive oil or mussel oil. In some embodiments, a method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation comprising the chemical composition. The method may include inhibiting and/or ameliorating inflammation and/or a malady associated with inflammation. In some embodiments, the subject may include a human or a nonhuman mammal. Nonhuman mammals may include equines, canines, or felines.

Abstract: Methods relating to methods for producing a needle coke precursor from slurry oil having low levels of nitrogen and sulfur. Nitrogen-containing compounds are removed by chromatography, followed by hydrotreating at relatively mild conditions that focus on the more easily-removed sulfur-containing compounds while largely preserving aromatic content of the slurry oil. The resulting needle coke precursor can be converted to a premium needle coke in a delayed coking system.

Abstract: A process of producing a light oil stream from slurry oils. The process begins by obtaining slurry oil from a fluid catalytic cracking unit. The slurry oil is then flowed over a fixed bed catalyst, consisting essentially of a non-metal catalyst, to produce a processed slurry oil. The processed slurry oil is then separated by boiling point to separate out the light oil stream.

Abstract: A process of producing a light oil stream from slurry oils. The process begins by obtaining slurry oil from a fluid catalytic cracking unit. The slurry oil is then flowed over a fixed bed catalyst, consisting essentially of a non-metal catalyst, to produce a processed slurry oil. The processed slurry oil is then separated by boiling point to separate out the light oil stream.

Abstract: Methods and apparatus relate to reducing content of nitrogen-containing compounds within slurry oil using a chromatographic based assembly, which may not affect aromatic content, prior to feeding the slurry oil into a coking system. The slurry oil passes through the chromatographic based assembly to upgrade the slurry oil and make the slurry oil suitable for feedstock in making needle coke. Further, a hydrotreater utilized in combination with the chromatographic based assembly may provide additional upgrading of the slurry oil.

Abstract: Certain metal-exchanged SUZ-4 zeolites have been prepared that have catalytic activity for the reduction of NOx in the exhaust of a hydrocarbon or alcohol fueled engine operated under fuel lean conditions. Initially the SUZ-4 zeolite contains alkali metal cations such as Li+, Na+, K+ and/or Cs+. These alkali metal cation-containing zeolites are partially exchanged with at least one of copper (II), silver (I), iron (III) or cobalt (II) ions. The resulting partially exchanged SUZ-4 zeolites display such activity and are stable under extreme hydrothermal aging conditions.

Abstract: Certain metal-exchanged SUZ-4 zeolites have been prepared that have catalytic activity for the reduction of NOx in the exhaust of a hydrocarbon or alcohol fueled engine operated under fuel lean conditions. Initially the SUZ-4 zeolite contains alkali metal cations such as Li+, Na+, K+ and/or Cs+. These alkali metal cation-containing zeolites are partially exchanged with at least one of copper (II), silver (I), iron (III) or cobalt (II) ions. The resulting partially exchanged SUZ-4 zeolites display such activity and are stable under extreme hydrothermal aging conditions.

Abstract: Certain metal-exchanged SUZ-4 zeolites have been prepared that have catalytic activity for the reduction of NOx in the exhaust of a hydrocarbon or alcohol fueled engine operated under fuel lean conditions. Initially the SUZ-4 zeolite contains alkali metal cations such as Li+, Na+, K+ and/or Cs+. These alkali metal cation-containing zeolites are partially exchanged with at least one of copper (II), silver (I), iron (III) or cobalt (II) ions. The resulting partially exchanged SUZ-4 zeolites display such activity and are stable under extreme hydrothermal aging conditions.

Abstract: Certain metal-exchanged SUZ-4 zeolites have been prepared that have catalytic activity for the reduction of NOx in the exhaust of a hydrocarbon or alcohol fueled engine operated under fuel lean conditions. Initially the SUZ-4 zeolite contains alkali metal cations such as Li+, Na+, K+ and/or Cs+. These alkali metal cation-containing zeolites are partially exchanged with at least one of copper (II), silver (I), iron (III) or cobalt (II) ions. The resulting partially exchanged SUZ-4 zeolites display such activity and are stable under extreme hydrothermal aging conditions.